GlobalData estimates that the global PCOS therapeutics market was valued at $656m in 2010, and is expected to grow at a static Compound Annual Growth Rate (CAGR) of 2.6% over the next eight years, to reach $804m by 2018. The growing treated population which is mainly due to expanding prevalence of co-morbid conditions such as diabetes, obesity and dyslipidemia will drive steady growth in PCOS therapeutics market.
Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018 Published: November 2011 No. of Pages: 78 Price: $ 3500 GlobalData, the industry analysis specialist, has released its new report, “Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global PCOS market. The report identifies the key trends shaping and driving the global PCOS market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global PCOS sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts. GlobalData estimates that the global Polycystic Ovarian Syndrome Therapeutics market was valued at $656m in 2010, and is expected to grow at a static Compound Annual Growth Rate (CAGR) of 2.6% over the next eight years, to reach $804m by 2018. The growing treated population which is mainly due to expanding prevalence of co-morbid conditions such as diabetes, obesity and dyslipidemia will drive steady growth in PCOS therapeutics market. Although treated patients are increasing but the market is showing static growth because of the unavailability of FDA approved and presence of off-label and generic products for treatment which are having lower patient satisfaction due to lower efficacy profiles since these products can not treat all the conditions such as hyperandrogenism, infertility, hyperglycemia and hirsutism, associated with PCOS. So still a huge unmet need exists in the management of treatment pattern with the help of more efficacious products which can cure all the conditions. In the pipeline of PCOS, majority of the participants are institutions or universities. Company participation is very low because most of the drugs which are under trial are generics and already being used for this indication either alone or in combination. Therefore current pipeline products are not going to impact the market significantly. Scope The report provides information on the key drivers and challenges of the PCOS market. Its scope includes - - Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) PCOS market revenues data from 2005 to 2010, forecast for eight years to 2018. - Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends. Pipeline candidates fall under major therapeutic classes such as Antiplatelate action, Ovulation inducer, Hypoglycemic, Antiandrogen, Progesterone derivative, Oral contraceptives, Antiobesity drugs and others. - Analysis of the current and future competition in the global PCOS market. Key market player covered is Reliance Life Sciences Pvt. Ltd. - Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications. - Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the PCOS therapeutic market. - Analysis of key recent licensing and partnership agreements in PCOS market. Reasons to buy The report will enhance your decision making capability. It will allow you to - - Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline. - Develop business strategies by understanding the trends shaping and driving the global PCOS market. - Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global PCOS market in future. - Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors. - Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage. - Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships. - What’s the next big thing in the global PCOS market landscape? – Identify, understand and capitalize. 1 Table of Contents 1 Table of Contents 2 1.1 List of Tables 6 1.2 List of Figures 6 2 Polycystic Ovarian Syndrome (PCOS) Therapeutics: Executive Summary 8 2.1 Polycystic Ovarian Syndrome (PCOS) Therapeutics Market is Forecast to Show Significant Growth until 2018 8 2.2 Need for FDA approved products 9 2.3 Weak pipeline with no disease modifying therapies 10 3 Polycystic Ovarian Syndrome (PCOS) Therapeutics: Introduction 11 3.1 Disease Overview 11 3.2 Epidemiology 11 3.3 Etiology and Pathology 14 3.3.1 Androgen Excess 15 3.3.2 Ovulatory Dysfunction 16 3.3.3 Insulin Resistance 16 3.3.4 Obesity and Adipose Tissue Dysfunction 16 3.3.5 Gonadotropin Abnormalities 16 3.3.6 Intrauterine Environment 16 3.3.7 Infancy to Adolescence 16 3.3.8 Genetics 17 3.3.9 Environmental Factors 17 3.4 Signs and Symptoms 18 3.5 Diagnosis 18 3.5.1 Careful History and Physical Examination 18 3.5.2 Laboratory Examination 18 3.6 Treatment and Management Pattern 19 3.6.1 Patient and Family Education 20 3.6.2 Non-Pharmacological Treatment 21 3.6.3 Pharmacological Treatment 21 3.7 Referral Pathway 22 3.8 GlobalData Pipeline Report Guidance 22 4 PCOS Therapeutics: Market Characterization 24 4.1 PCOS Therapeutics Market Size (2005–2010) – Global 24 4.2 PCOS Therapeutics Market Forecast (2010–2018) – Global 25 4.3 PCOS Therapeutics Market Size (2005–2010) – The US 26 4.4 PCOS Therapeutics Market Forecast (2010–2018) – The US 27 4.5 PCOS Therapeutics Market Size (2005–2010) – France 28 4.6 PCOS Therapeutics Market Forecast (2010–2018) – France 29 4.7 PCOS Therapeutics Market Size (2005–2010) – Germany 31 4.8 PCOS Therapeutics Market Forecast (2010–2018) – Germany 32 4.9 PCOS Therapeutics Market Size (2005–2010) – Italy 33 4.10 PCOS Therapeutics Market Forecast (2010–2018) – Italy 34 4.11 PCOS Therapeutics Market Size (2005–2010) – Spain 35 4.12 PCOS Therapeutics Market Forecast (2010–2018) – Spain 36 4.13 PCOS Therapeutics Market Size (2005–2010) – The UK 37 4.14 PCOS Therapeutics Market Forecast (2010–2018) – The UK 38 4.15 PCOS Therapeutics Market Size (2005–2010) – Japan 40 4.16 PCOS Therapeutics Market Forecast (2010–2018) – Japan 41 4.17 Drivers and Barriers for the PCOS therapeutics market 42 4.17.1 Drivers for the PCOS therapeutics market 42 4.17.2 Barriers for the PCOS therapeutics market 42 4.17.3 Opportunity and Unmet need analysis 43 4.18 Key Takeaway 44 5 PCOS Therapeutics: Competitive Assessment 46 5.1 Overview 46 5.2 Strategic Competitor Assessment 46 5.3 Product Profiles for the Major Products in the PCOS Therapeutics Market 47 5.3.1 Oral contraceptives 47 5.3.2 Long-acting Gonadotropin-Releasing Hormone (GnRH) analogues 49 5.3.3 Insulin sensitising agents 50 5.3.4 Ovulation inducer 51 5.3.5 Antiandrogens/ Hirsutism treatment 52 Spiranolactone 52 5.4 Key Takeaway 53 6 PCOS Therapeutics: Pipeline Assessment 54 6.1 Overview 54 6.2 Strategic Pipeline Assessment 54 6.3 PCOS Therapeutics Pipeline – Pipeline by Phase of Development 55 6.3.1 PCOS Therapeutics – Phase III Pipeline 55 6.3.2 PCOS Therapeutics – Phase II/III Pipeline 56 6.3.3 PCOS Therapeutics – Phase II Pipeline 56 6.3.4 PCOS Therapeutics – Phase I/II Pipeline 56 6.3.5 Technology Trends Analytic Framework 56 6.4 PCOS Therapeutics Market –Pipeline by Mechanism of Action 58 6.5 PCOS Therapeutics – Promising Drugs under Clinical Development 60 6.6 Molecule Profile for Promising Drugs under Clinical Development 60 6.6.1 R-TPR-020 60 6.7 Key Takeaway 60 7 PCOS Therapeutics: Clinical Trials Mapping 61 7.1 Clinical Trials by Region/Country (US, EU5 and Japan) 61 7.2 Clinical Trials by Phase 62 7.3 Clinical Trials by Trial Status 63 7.4 Prominent Sponsors 64 7.5 Top Companies Participating in PCOS Therapeutics Clinical Trials 66 8 Strategic Assessment 67 8.1 Key Events Impacting the Future Market 67 8.2 PCOS Therapeutics: Implications for Future Market Competition 68 9 PCOS Therapeutics: Future Players 70 9.1 Introduction 70 9.2 Company Profiles 71 9.2.1 Reliance Life Sciences Pvt. Ltd. 71 10 PCOS Therapeutics: Licensing and Partnership Deals 72 11 PCOS Therapeutics: Appendix 73 11.1 Market Definitions 73 11.2 Abbreviations 73 11.3 Research Methodology 74 11.3.1 Coverage 75 11.3.2 Secondary Research 75 11.3.3 Forecasting 75 11.3.4 Primary Research 77 11.3.5 Expert Panel Validation 78 11.4 Contact Us 78 11.5 Disclaimer 78 11.6 Bibliography 78 About Us: ReportsnReports is an online library of over 100,000+ market research reports and in-depth market research studies & analysis of over 5000 micro markets. We provide 24/7 online and offline support to our customers. Get in touch with us for your needs of market research reports. Follow us on Twitter: http://twitter.com/marketsreports Our Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689 Contact: Mr.Priyank 7557 Rambler road, Suite727,Dallas,TX75231 Tel: + 1 888 391 5441 E-mail: email@example.com http://www.reportsnreports.com Visit our Market Research Blog
Pages to are hidden for
"Polycystic Ovarian Syndrome (PCOS) Therapeutics - Pipeline Assessment and Market Forecasts to 2018"Please download to view full document